VCs 'Com­ple­men­t' Eu­ro­pean biotech with $79M for reti­nal AAV gene ther­a­py tri­al next year

Com­ple­ment Ther­a­peu­tics raised a €72 mil­lion ($79.6 mil­lion) Se­ries A to bankroll a Phase Ib of its AAV gene ther­a­py in ge­o­graph­ic at­ro­phy.

The dis­ease, which leads to blind­ness, gots its first ap­proved treat­ment this year via Apel­lis’ Syfovre. Iver­ic Bio is close be­hind.

Like those drug de­vel­op­ers, the UK and Ger­man start­up is go­ing af­ter the com­ple­ment cas­cade, thought to con­tribute to mul­ti­ple dis­eases. In­stead of fre­quent in­jec­tions, Com­ple­ment wants a one-and-done gene ther­a­py to thwart the on­set of blind­ness, and the biotech will test that ap­proach start­ing in Sep­tem­ber or Oc­to­ber 2024, CEO and man­ag­ing di­rec­tor Rafiq Hasan told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER